RT Journal Article SR Electronic T1 Mapping out asthma in the out-patient clinic – The MAPOUT II study JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA5008 DO 10.1183/13993003.congress-2016.PA5008 VO 48 IS suppl 60 A1 Asger Sverrild A1 Vibeke Backer A1 Celeste Porsbjerg YR 2016 UL http://erj.ersjournals.com/content/48/suppl_60/PA5008.abstract AB Background Most studies in asthma only include selected groups of patients with many similarities in test results and clinical outcomes between subjects. The real life asthma population is far more heterogeneous with huge variations in clinical features and test results that are less well studied.Aim The MAPOUT II study describes a clinically representative real-life asthma population in terms of clinical presentation and test outcomes over a 1-year follow-up.Methods Subjects with possible asthma referred to a tertiary hospital clinic were enrolled over one year, and followed up 12 months later. Spirometry, FeNO, skin prick test, bronchoprovocation tests for airway hyperreactivity (AHR), induced sputum and ACQ were performed at baseline and at follow-up. Differences in clinical outcomes and test results were described at baseline and follow-up.Results A total of 151 (79%) had objectively verified asthma. 60% were females; mean (min; max) age was 31 (15; 63); mean (min; max) ACQ was 1.4 (0.0; 4.6), mean (min; max) percent predicted FEV1 was 99 (45; 167), 60% were atopic; 71% had AHR and 19% had sputum eosinophils ≥3%. At follow-up 11% had sputum eosinophils ≥3%, and 54% of the asthmatics had AHR. Predictors of AHR at follow-up were lower FEV1, a higher ACQ-score and presence of AHR at baseline. Subjects with AHR at follow-up continued to be more symptomatic than asthmatics without AHR.Conclusion Asthmatics referred for specialist care are heterogeneous, and the majority of subjects presented with non-eosinophilic asthma and a normal FEV1, but with AHR that remained despite treatment with ICS. The results call for attention toward the large majority of subjects with non-eosinophilic asthma, AHR and continuous symptoms.